PortalPublikationenAdjuvant trastuzumab in HER2-positive breast cancer.

Adjuvant trastuzumab in HER2-positive breast cancer.

Standard

Adjuvant trastuzumab in HER2-positive breast cancer. / Slamon, Dennis; Eiermann, Wolfgang; Robert, Nicholas; Pienkowski, Tadeusz; Martin, Miguel; Press, Michael; Mackey, John; Glaspy, John; Chan, Arlene; Pawlicki, Marek; Pinter, Tamas; Valero, Vicente; Liu, Mei-Ching; Sauter, Guido; von Minckwitz, Gunter; Visco, Frances; Bee, Valerie; Buyse, Marc; Bendahmane, Belguendouz; Tabah-Fisch, Isabelle; Lindsay, Mary-Ann; Riva, Alessandro; Crown, John; Group, Breast Cancer International Research.

in: NEW ENGL J MED, Jahrgang 365, Nr. 14, 14, 2011, S. 1273-1283.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Slamon, D, Eiermann, W, Robert, N, Pienkowski, T, Martin, M, Press, M, Mackey, J, Glaspy, J, Chan, A, Pawlicki, M, Pinter, T, Valero, V, Liu, M-C, Sauter, G, von Minckwitz, G, Visco, F, Bee, V, Buyse, M, Bendahmane, B, Tabah-Fisch, I, Lindsay, M-A, Riva, A, Crown, J & Group, BCIR 2011, 'Adjuvant trastuzumab in HER2-positive breast cancer.', NEW ENGL J MED, Jg. 365, Nr. 14, 14, S. 1273-1283. <http://www.ncbi.nlm.nih.gov/pubmed/21991949?dopt=Citation>

APA

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M-C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., ... Group, B. C. I. R. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. NEW ENGL J MED, 365(14), 1273-1283. [14]. http://www.ncbi.nlm.nih.gov/pubmed/21991949?dopt=Citation

Vancouver

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEW ENGL J MED. 2011;365(14):1273-1283. 14.

Bibtex

@article{48f1eb9748cc4c2ba1bc69ce66b68fc7,
title = "Adjuvant trastuzumab in HER2-positive breast cancer.",
abstract = "Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.",
keywords = "Humans, Female, Middle Aged, Survival Rate, Disease-Free Survival, Chemotherapy, Adjuvant, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Anthracyclines/adverse effects/therapeutic use, Antibodies, Monoclonal/adverse effects/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Breast Neoplasms/*drug therapy/mortality, Heart Failure/chemically induced, Leukemia/chemically induced, *Receptor, erbB-2, Stroke Volume/drug effects, Humans, Female, Middle Aged, Survival Rate, Disease-Free Survival, Chemotherapy, Adjuvant, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Anthracyclines/adverse effects/therapeutic use, Antibodies, Monoclonal/adverse effects/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Breast Neoplasms/*drug therapy/mortality, Heart Failure/chemically induced, Leukemia/chemically induced, *Receptor, erbB-2, Stroke Volume/drug effects",
author = "Dennis Slamon and Wolfgang Eiermann and Nicholas Robert and Tadeusz Pienkowski and Miguel Martin and Michael Press and John Mackey and John Glaspy and Arlene Chan and Marek Pawlicki and Tamas Pinter and Vicente Valero and Mei-Ching Liu and Guido Sauter and {von Minckwitz}, Gunter and Frances Visco and Valerie Bee and Marc Buyse and Belguendouz Bendahmane and Isabelle Tabah-Fisch and Mary-Ann Lindsay and Alessandro Riva and John Crown and Group, {Breast Cancer International Research}",
year = "2011",
language = "English",
volume = "365",
pages = "1273--1283",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "14",

}

RIS

TY - JOUR

T1 - Adjuvant trastuzumab in HER2-positive breast cancer.

AU - Slamon, Dennis

AU - Eiermann, Wolfgang

AU - Robert, Nicholas

AU - Pienkowski, Tadeusz

AU - Martin, Miguel

AU - Press, Michael

AU - Mackey, John

AU - Glaspy, John

AU - Chan, Arlene

AU - Pawlicki, Marek

AU - Pinter, Tamas

AU - Valero, Vicente

AU - Liu, Mei-Ching

AU - Sauter, Guido

AU - von Minckwitz, Gunter

AU - Visco, Frances

AU - Bee, Valerie

AU - Buyse, Marc

AU - Bendahmane, Belguendouz

AU - Tabah-Fisch, Isabelle

AU - Lindsay, Mary-Ann

AU - Riva, Alessandro

AU - Crown, John

AU - Group, Breast Cancer International Research

PY - 2011

Y1 - 2011

N2 - Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.

AB - Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.

KW - Humans

KW - Female

KW - Middle Aged

KW - Survival Rate

KW - Disease-Free Survival

KW - Chemotherapy, Adjuvant

KW - Intention to Treat Analysis

KW - Antibodies, Monoclonal, Humanized

KW - Anthracyclines/adverse effects/therapeutic use

KW - Antibodies, Monoclonal/adverse effects/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Breast Neoplasms/drug therapy/mortality

KW - Heart Failure/chemically induced

KW - Leukemia/chemically induced

KW - Receptor, erbB-2

KW - Stroke Volume/drug effects

KW - Humans

KW - Female

KW - Middle Aged

KW - Survival Rate

KW - Disease-Free Survival

KW - Chemotherapy, Adjuvant

KW - Intention to Treat Analysis

KW - Antibodies, Monoclonal, Humanized

KW - Anthracyclines/adverse effects/therapeutic use

KW - Antibodies, Monoclonal/adverse effects/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Breast Neoplasms/drug therapy/mortality

KW - Heart Failure/chemically induced

KW - Leukemia/chemically induced

KW - Receptor, erbB-2

KW - Stroke Volume/drug effects

M3 - SCORING: Journal article

VL - 365

SP - 1273

EP - 1283

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 14

M1 - 14

ER -